Skip to main content

Plaquex IVs

Plaquex®

plaque ivs

History of Plaquex Therapy

In mid-1995, Dr. Sam Baxas faced a personal challenge when his wife, Heidi, began experiencing chest pains. After two unsuccessful balloon angioplasties, Dr. Sam sought alternative treatments and discovered an ancient remedy from Germany. This led to Heidi becoming the first patient to receive what we now know as Plaquex therapy. Remarkably, her chest pains disappeared, and with regular maintenance, they never returned.

Dr. Sam was amazed at the effectiveness of Plaquex compared to traditional chelation therapy, leading him to treat other patients with the same success. Over the past 25 years, this revolutionary treatment has gained traction, with hundreds of doctors in the U.S. and around the world now administering it, benefiting tens of thousands of patients. Today, Dr. Sam’s daughters continue the mission of spreading awareness about Plaquex therapy to both physicians and patients.

The Plaquex® Formula has a rich history, having been utilized for over 70 years in approximately a quarter of the world’s countries. Initially developed to dissolve fatty emboli during trauma surgery, its application has since expanded to treat plaque deposits, particularly in conjunction with EDTA chelation infusions. Due to the impressive outcomes, Plaquex has established itself as an independent treatment option.

Beyond its primary use for removing fatty and hardened plaque from blood vessels, Plaquex therapy has shown promise in anti-aging applications. Many practitioners have observed that patients appear healthier and more youthful after completing around 20 treatment sessions. The formula also addresses liver and kidney diseases, protects the stomach lining from NSAID damage, and has been beneficial for psoriasis patients.

In 2006, the introduction of Plaquex® Oral Gel Capsules allowed for continued treatment between IV sessions and after the infusion series.

At Dr. Erica Oberg’s clinic, we emphasize quality and efficacy, proudly utilizing Plaquex to help our patients achieve optimal health. Our team is here to answer your questions about treatments and assist you in your wellness journey.

For further information about Plaquex, including studies and FAQs, we encourage you to explore our website and reach out for assistance. Together, let’s take steps towards a healthier future.

Book Now

References

1 Elevation of HDL, LDL, and liver enzymes in the beginning which normalize with continuing treatment

Leuschner, F. A. Leuschner. Research report no. 0050/84 of December 27, 1983
Maeda, A. et al. Gendai no Shinryo 22 (1980) 189-192 and 1461-1465
Fasoli, A.  Therap. Select. Risk/Benefit Assess. Hypolipid. Drugs
G. Ricci et al. (eds.) Raven Press: New York 1982, 257-262
Suo, T. et al.   Kiso to Rinsho 15 (1981) 3046-3051
Belousova, S.S. et al.  Kardiologiya 25 (1985) 112-115
Izumi, H.  et al. 11th Proceed Jap. Atheroscl. Socl, Tokyo 1979
Nakamura, H.  et al. Jap J. New. Rem. Clin. 22 (1973) 1565-1575
Spigai, C. Med. Heute 19 (1970) 197-198
Thurnherr A. Therapiewoche 7 (1956) 116
Friehe, H., R. Fontaine Report no. 840160 of December 16, 1978
Arsenio, L.  et al. Clin. Ter. 114 (1985) 117-127
Tomasevic, M. Unpublished report no. 842746
Takahashi, S.  Shinryo to Shinyaku 17 (1980) 3051-3064
Blagosklonov, A.S.  et al. Kardiologiya 26 (1986) 35-38

2 Angina Pectoris

 Serkova, V.K. Klin. Med. (Moscow) 64 (1986) 91-95
Spesivtseva, V. G. et al., Lipostabil Symposium Moscow, Nov. 1984
Kalmykova, V.I., E. B. Zakharova, Sov. Med. 4 (1989) 5-9

  Peripheral Vascular

 Klemm, J. In: Phosphatidylcholine. H. Peeters (ed.) Springer: Berlin 1976, 237-243
Luczac, Z., R. Leutschaft.  Unpublished report no. 842762
Pristautz, H.  Munch. Med. Wschr. 117 (1975) 583-586
Hevelke, G. et al.  Med. Welt 30 (1980) 593-602

  Liver disease

 Salvioli, G. et al. Il Fegato 21 (1975) 5-25 and: 4th Int. Sympos. Atheroscl., Tokyo 1976 and:
Diab. Obes. Hyperlipoprot., Cupaldi, V. et al. (eds.), Academic Press: New York 1987

 Salvioli, G.  Scand J. Gastroenterology 12 (1977) 841-847
Salvioli, G. et al. Gut 19 (1978) 844-850
Gaskina, T.K. et al. Voprosy meditsinskoi khimii 331 (1987) 96-99

 Cell Membranes

 Ehrly, A.M. Report no. 842276 of March 17, 1975 – and R. Blendin in: Phosphatidylcholine, H. Peeters (ed.) Springer Berlin  1976, 228-236
Blagosklonov, A.S. et al. Kardiologiya 26 (1986) 35-38
3 Nei’mark Al, Zhukov, VN et al.  Use of isradipine and EPL for protection of the kidney during extracorporal lithotripsy
Urologiia I Nefrologiia. (6):19-21, 1998 Nov-Dec
4 Kuntz, E.  The “essential” phospholipids in hepatology – 50 years of experimental and clinical experiences
Z Gastroenterol (Suppl 2) 1991: 29:7-13

Cerebrolysin, a neurotrophic peptide, demonstrates significant potential in supporting cognitive function and mental acuity. Widely recognized for its neuroprotective and neuroregenerative properties, Cerebrolysin promotes brain health by enhancing neuronal survival, increasing neurotransmitter activity, and fostering synaptic connectivity. This peptide shows promise in addressing age-related cognitive decline, memory impairment, and neurodegenerative conditions.

Additionally, other peptides such as Thymosin alpha-1, PT-141, and Melanotan II, among others, offer diverse benefits ranging from immune system modulation to sexual health enhancement and skin rejuvenation.

Close Menu